ESTRO 2024 - Abstract Book

S142 ESTRO 2024 focal boost is probably feasible, provided that OAR constraints are prioritized. Possible dose is also dependent on the location of the recurrence. Its potential benefit should urgently be investigated in prospective clinical trials. Invited Speaker

These results are published in Clin Transl Radiat Oncol 2023 Sep 23: 43: 100684.

DOI: 10.1016/j.ctro.2023.100684

•

3612

A Delphi consensus study on stereotactic body radiotherapy for oligometastatic renal cell carcinoma (RCC), an ESTRO study – with EAU endorsement

Giulia Marvaso

University of Milan (Milan, Italy), Oncology and Hemato-Oncology at the University of Milan, Milan, Italy. Istituto Europeo di Oncologia, Division of Radiotherapy, Milan, Italy

Abstract:

Background As of 2023, no guidelines exist on the management of oligometastatic renal cell carcinoma (RCC) with stereotactic ablative radiotherapy (SABR). The purpose of this ESTRO project is to explore the expert opinion on the management of oligometastatic RCC patients using SABR on extracranial metastases, with the aim of developing consensus recommendations for patient selection, treatment doses, and concurrent systemic therapy. Methods A questionnaire on SABR in oligometastatic RCC was prepared by a core group and reviewed by a panel of 10 prominent experts in the field. The final version of the questionnaire included 38 questions dealing with controversial issues related to oligometastatic RCC and SABR. It was implemented online via Google Forms and sent to clinicians identified as key opinion leaders in 2022. The Delphi consensus methodology was applied and involved sending three rounds of questionnaires to the experts. The consensus threshold was set to 80%, while an agreement of between 65% and 80% was considered a major agreement. Results Thirty-four experts (63%) agreed to participate and, among them, 25 participated in the three rounds of the Delphi consensus. At the end of the third round, participants were able to find consensus on 8 out of 37 questions. Specifically, panelists agreed to apply no restrictions regarding age (100%) and primary RCC histology (92%) for SABR candidates, on the upper threshold of three lesions to offer an ablative treatment in the oligoprogressive patients and on the concomitant management of Immune checkpoint inhibitor. SABR was indicated as the treatment modality of choice for RCC bone (80%) and for adrenal oligometastases(88%). No consensus or major agreement was reached regarding the appropriate schedule, but the majority of the poll (54% - 58%) retained the every other day schedule as the optimal choice for all the investigated sites. Conclusion The current ESTRO Delphi consensus may provide useful direction for the application of SABR in oligometastatic RCC and highlight the key areas of ongoing debate, perhaps directing future research efforts to close knowledge gaps.

3613

ESTRO-ACROP consensus guideline for the management of radiodermatitis

Elizabeth Forde 1 , Ludwig Van den Berghe 2 , Monica Buijs 3 , Antonella Cardone 4 , Jacqueline Daly 5 , Pierfrancesco Franco 6 , Naman Julka-Anderson 7 , Wolfgang Lechner 8 , Laure Marignol 1 , Heather Nisbeth 9 , Giulia Marvaso 10,11 , Anita O'Donovan 1 , Nicola S. Russell 12 , Philipp Scherer 13